REGENXBIO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.44 USD | -1.53% |
|
-8.26% | -13.98% |
| May. 09 | UBS Adjusts Price Target on REGENXBIO to $39 From $43, Maintains Buy Rating | MT |
| May. 08 | Transcript : REGENXBIO Inc., Q1 2024 Earnings Call, May 08, 2024 |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,511 | 1,697 | 1,399 | 981.9 | 789.7 | 760.5 | - | - |
| Enterprise Value (EV) 1 | 1,215 | 1,221 | 941.1 | 617.3 | 514.4 | 658.9 | 603.5 | 763.3 |
| P/E ratio | -15.9 x | -15.2 x | 11.2 x | -3.49 x | -2.98 x | -3.15 x | -8.1 x | -6.38 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 42.9 x | 11 x | 2.97 x | 8.71 x | 8.75 x | 7.56 x | 3.03 x | 2.99 x |
| EV / Revenue | 34.5 x | 7.9 x | 2 x | 5.48 x | 5.7 x | 6.55 x | 2.4 x | 3 x |
| EV / EBITDA | -8.56 x | -11 x | 5.55 x | -2.47 x | -2.05 x | -3.59 x | 32.6 x | - |
| EV / FCF | -10.2 x | -15.1 x | - | -2.59 x | -2.25 x | -3.71 x | 3.83 x | -5.82 x |
| FCF Yield | -9.83% | -6.63% | - | -38.6% | -44.4% | -27% | 26.1% | -17.2% |
| Price to Book | 3.37 x | 4.5 x | 1.83 x | 1.9 x | 2.54 x | 2.97 x | 2.4 x | 2.58 x |
| Nbr of stocks (in thousands) | 36,874 | 37,408 | 42,769 | 43,294 | 43,992 | 49,256 | - | - |
| Reference price 2 | 40.97 | 45.36 | 32.70 | 22.68 | 17.95 | 15.44 | 15.44 | 15.44 |
| Announcement Date | 2/26/20 | 3/1/21 | 3/1/22 | 2/28/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 35.23 | 154.6 | 470.3 | 112.7 | 90.24 | 100.6 | 251.2 | 254 |
| EBITDA 1 | -141.8 | -110.8 | 169.5 | -250 | -250.8 | -183.5 | 18.53 | - |
| EBIT 1 | -149 | -119.2 | 160 | -262.9 | -268.1 | -239.4 | -119.7 | -189.1 |
| Operating Margin | -422.89% | -77.14% | 34.01% | -233.2% | -297.12% | -237.96% | -47.65% | -74.43% |
| Earnings before Tax (EBT) 1 | -97.49 | -106 | 141.2 | -280.4 | -263.6 | -257.9 | -214.9 | -176.1 |
| Net income 1 | -94.73 | -111.2 | 127.8 | -280.3 | -263.5 | -228.4 | -106.6 | -140.7 |
| Net margin | -268.88% | -71.98% | 27.18% | -248.68% | -291.99% | -227.03% | -42.45% | -55.37% |
| EPS 2 | -2.580 | -2.980 | 2.910 | -6.500 | -6.020 | -4.908 | -1.906 | -2.420 |
| Free Cash Flow 1 | -119.4 | -80.93 | - | -238.2 | -228.4 | -177.8 | 157.5 | -131.2 |
| FCF margin | -338.96% | -52.36% | - | -211.32% | -253.06% | -176.73% | 62.7% | -51.65% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | 850.17% | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/26/20 | 3/1/21 | 3/1/22 | 2/28/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 398.7 | 22.22 | 32.65 | 26.51 | 31.34 | 19.14 | 19.98 | 28.91 | 22.21 | 15.62 | 24.13 | 25.59 | 28 | 21.97 | 103.2 |
| EBITDA | 316.2 | -68.94 | -59.89 | -67.5 | -53.64 | -61.98 | -68.67 | -60.59 | - | - | - | - | - | - | - |
| EBIT 1 | 313.6 | -71.53 | -62.53 | -71.04 | -57.77 | -66.16 | -73.11 | -64.96 | -63.9 | -61.76 | -62.25 | -62.69 | -59.01 | -62.3 | -4.167 |
| Operating Margin | 78.66% | -321.93% | -191.53% | -267.97% | -184.31% | -345.68% | -365.96% | -224.67% | -287.68% | -395.35% | -257.97% | -245% | -210.78% | -283.58% | -4.04% |
| Earnings before Tax (EBT) 1 | 307.4 | -76.76 | -68.18 | -75.48 | -59.98 | -66.68 | -72.06 | -61.87 | -63.04 | -63.33 | -62.69 | -64.73 | -65.78 | -76 | -81 |
| Net income 1 | 294 | -76.72 | -68.18 | -75.48 | -59.94 | -66.68 | -72.06 | -61.87 | -62.89 | -63.33 | -57.94 | -56.57 | -54.12 | -60.14 | 35.62 |
| Net margin | 73.75% | -345.32% | -208.82% | -284.72% | -191.21% | -348.4% | -360.72% | -213.97% | -283.12% | -405.39% | -240.12% | -221.09% | -193.32% | -273.74% | 34.51% |
| EPS 2 | 6.670 | -1.790 | -1.580 | -1.750 | -1.380 | -1.530 | -1.660 | -1.410 | -1.430 | -1.380 | -1.220 | -1.194 | -1.130 | -1.280 | -0.2350 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/1/22 | 5/4/22 | 8/3/22 | 11/3/22 | 2/28/23 | 5/3/23 | 8/2/23 | 11/8/23 | 2/27/24 | 5/8/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | 2.79 |
| Net Cash position 1 | 296 | 476 | 457 | 365 | 275 | 102 | 157 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -119 | -80.9 | - | -238 | -228 | -178 | 158 | -131 |
| ROE (net income / shareholders' equity) | -19.8% | -26.9% | 22.4% | -43.8% | -63.7% | -83.3% | -4.18% | -3.7% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 12.20 | 10.10 | 17.80 | 11.90 | 7.080 | 5.210 | 6.420 | 5.990 |
| Cash Flow per Share 2 | - | -1.450 | 4.980 | -4.810 | -4.990 | -2.680 | 3.860 | - |
| Capex 1 | 11.7 | 26.9 | 84.2 | 30.7 | 9.96 | 8.23 | 7.89 | 5.93 |
| Capex / Sales | 33.26% | 17.38% | 17.9% | 27.26% | 11.04% | 8.18% | 3.14% | 2.34% |
| Announcement Date | 2/26/20 | 3/1/21 | 3/1/22 | 2/28/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
15.44
USD
Average target price
39.08
USD
Spread / Average Target
+153.13%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.98% | 761M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- RGNX Stock
- Financials REGENXBIO Inc.
